Pierre Fabre Medicament
Records under this name other than the patents Pierre Fabre Medicament holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 57 patents it holds.
Back to Pierre Fabre Medicament
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,766,959 | ANTI-C10ORF54 Antibodies and Uses Thereof now held by Igenica, Inc. In force · High confidence | In force | High confidence | |
| US 12,312,336 | Inhibitors of Raf Kinases now held by Pierre Fabre Médicament, SAS In force · High confidence | In force | High confidence | |
| US 12,569,496 | Treatment of Cancer with a Raf Inhibitor now held by Pierre Fabre Médicament, SAS In force · Low confidence | In force | Low confidence | |
| US 12,209,129 | Anti-Met Fab-Fc for the Treatment of a Tumor And/Or Metastasis now held by Pierre Fabre Médicament In force · High confidence | In force | High confidence | |
| US 12,692,248 | Solid State Forms of (S)-N-(3-(2-(((R)-1-Hydroxypropan-2-YL)AMINO)-6-Morpholinopyridin-4-YL)-4-Methylphenyl)-3-(2,2,2-Trifluoroethyl)PYRROLIDINE-1-Carboxamide and Salts Thereof now held by Pierre Fabre Médicament, SAS In force · High confidence | In force | High confidence | |
| US 10,028,948 | Chromone Derivative as a Dopamine D3 Receptor Antagonist for Its Use for the Treatment of Autism Spectrum Disorder Lapsed on the fee record Ended Jul 24, 2026 · Medium confidence | Lapsed on the fee record | Ended Jul 24, 2026 | Medium confidence |
| US 8,945,871 | Novel Anti-Igf-Ir Antibodies and Uses Thereof Term ended Term ended Jul 21, 2026 · High confidence | Term ended | Term ended Jul 21, 2026 | High confidence |
| US 9,061,015 | Stable Solid Dispersion of a Derivative of Vinca Alkaloid and Process for Manufacturing It Term ended Term ended Jul 18, 2026 · High confidence | Term ended | Term ended Jul 18, 2026 | High confidence |
| US 11,340,233 | A New Universal Method to Capture and Analyze Adcs for Characterization of Drug Distribution and the Drug-To-Antibody Ratio in Biological Samples Lapsed on the fee record Ended May 24, 2026 · High confidence | Lapsed on the fee record | Ended May 24, 2026 | High confidence |
| US 8,697,064 | Nitrogenated Derivatives of Pancratistatin Lapsed on the fee record Ended Apr 15, 2026 · High confidence | Lapsed on the fee record | Ended Apr 15, 2026 | High confidence |